History of aspirin Hermann Hildebrandt). In 1894, the young chemist Felix Hoffmann joined the pharmaceutical group. Dreser, Eichengrün and Hoffmann would be the key figures in the development of acetylsalicylic acid as the drug Aspirin (though their respective roles have been the subject of some contention). In 1897, Hoffmann started working to find a less irritating substitute for salicylic acid. It is generally accepted that he turned to this idea because his father was suffering the side effects of taking sodium salicylate for rheumatism. In 1853, Charles Frédéric Gerhardt had published the first methods to prepare acetylsalicylic acid. In the course of his
Cromoglicic acid may act by inhibiting calcium influx. Cromoglicate is classified as a chromone. Cromolyn is also being tested as a drug to treat insulin-induced lipoatrophy. Cromolyn is also known to bind S100P protein and disrupt the interaction with RAGE. Cromoglicic acid Cromoglicic acid (INN) (also referred to as cromolyn (USAN), cromoglycate (former BAN), or cromoglicate) is traditionally described as a mast cell stabilizer, and is commonly marketed as the sodium salt sodium cromoglicate or cromolyn sodium. This drug prevents the release of inflammatory chemicals such as histamine from mast cells. Because of their convenience (and perceived safety), leukotriene receptor antagonists have